Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence - Top-Institutions - MDSpire

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence

By
Shogo Baba
Mami Koketsu
Hajime Kuroda
Megumi Suzuki
Hiroshi Nishihara
Yasutaka Kato
Hiroyuki Kawami
Oi Harada
May 20, 2026
0 min

Frontiers In Oncology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology
- Breast Cancer
#2

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Oncology
- Breast Cancer
#3

Dana-Farber Cancer Institute

Boston, Massachusetts
Key Differentiators
- Oncology
- Breast Cancer
#4

Yale Cancer Center

New Haven, Connecticut
Key Differentiators
- Oncology
- Breast Cancer
#5

Winship Cancer Institute at Emory University

Atlanta, Georgia
Key Differentiators
- Oncology
- Breast Cancer

Original Source(s)

Frontiers In Oncology

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence

by Shogo Baba, Mami Koketsu, Hajime Kuroda, Megumi Suzuki, Hiroshi Nishihara, Yasutaka Kato, Hiroyuki Kawami, Oi Harada
May 20, 2026

Related Content

Blood Cancer Journal

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Frontiers In Immunology

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

by Chunyu Zhang, Shu Bu, Xiaoyu Wang, Xin Shen, Yang Du, Jiangnan Yang, Zhiwei Miao
May 29, 2026

Frontiers In Oncology

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications